Product name
Synthetic Inhibitors for Ras-Raf Mediated Signal Transduction from University BochumSummary
Inhibitors preventing the binding of the Raf-Kinase to the Ras/GTPComplexOrganization name
rubitec GmbH - the technology transfer agency of the Ruhr University BochumProfile
Approximately 400.000 new cases of cancer are annually reported in Germany alone. 20-30 % of all tumors involve a tumorigenic mutated Ras-Protein, which irreversibly binds a GTP and thus leads to an uncontrolled cell-division signal. Signal transduction proceeds by the binding of a Raf-Kinase to the Ras/GTPComplex.
Scientists of the Ruhr-University Bochum have identified new potential inhibitors which in a specific manner prevent the binding of the Raf-Kinase to the Ras/GTPComplex. The structures of these inhibitors are based on rational design.
Application
- The target protein - tumorigenic mutated Ras-Protein - mostly occurs in adeno- carcinoma of the pancreas (90 %) and the intestine (50 %). Both belong to the five most common causes of cancer death
- When used as pharmacological active substances, the new inhibitors are applicable to both forms of cancer.
Advantages
- The application includes multiple structures of potential inhibitors.
- The inhibitors have high specificity to the tumorigenic mutated Ras/GTP Complex.
- The inhibitors can be manufactured by simple chemical synthesis.
On behalf of the Ruhr-University Bochum rubitec GmbH offers for "Inhibitors for Ras-Raf mediated signal Transduction" Patent licenses, buy as well as further co-development.
Developmental Status
The Inhibitors for Ras-Raf mediated signal transduction was positiv tested in vitro.
German Patent application has been filed.
Contact
rubitec GmbH
Dietmar Tappe
patente(at)ruhr-unibochum. de
Description File
Synthetic_Inhibitors_for_Ras-Raf_Mediated_Signal_Transduction.pdf
print this page
